Classification of Drug Information Questions Related

Review Classification of Drug Information Questions related questions and content

A provider may consider testing for CYP2D6 variants prior to starting tamoxifen for breast cancer to:

  • A. Ensure the patient will not have increased adverse effects from the tamoxifen
  • B. Identify if the patient is a poor metabolizer, potentially reducing conversion to active metabolites
  • C. Evaluate risk of drug interactions with tamoxifen
  • D. Determine if the patient requires a higher dose due to ultra-rapid metabolism
Correct Answer: B

Rationale: CYP2D6 testing identifies poor metabolizers who may not convert tamoxifen to its active form (endoxifen), impacting efficacy, not just ADRs or interactions .